1. Inicio
  2. Publicaciones
  3. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Del Amo J.
  • Polo R.
  • Moreno S.
  • Cabello A.
  • Iribarren J.A.
  • Curran A.
  • MacÍas J.
  • Dueñas C.
  • Mariño A.I.
  • De La Cámara S.P.
  • Díaz A.
  • Arribas J.R.
  • Jarrín I.
  • Hernán M.A.

Grupos

Abstract

Background: Effective, safe, and affordable antivirals are needed for coronavirus disease 2019 (COVID-19). Several lines of research suggest that tenofovir may be effective against COVID-19, but no large-scale human studies with appropriate adjustment for comorbidities have been conducted.Methods: We studied HIV-positive individuals on antiretroviral therapy (ART) in 2020 at 69 HIV clinics in Spain. We collected data on sociodemographics, ART, CD4+cell count, HIV-RNA viral-load, comorbidities and the following outcomes: laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19 hospitalization, intensive care unit (ICU) admission and death. We compared the 48-week risks for individuals receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and other regimes. All estimates were adjusted for clinical and sociodemographic characteristics via inverse probability weighting.Results: Of 51 558 eligible individuals, 39.6% were on TAF/FTC, 11.9% on TDF/FTC, 26.6% on ABC/3TC, 21.8% on other regimes. There were 2402 documented SARS-CoV-2 infections (425 hospitalizations, 45 ICU admissions, 37 deaths). Compared with TAF/FTC, the estimated risk ratios (RR) (95% confidence interval) of hospitalization were 0.66 (0.43, 0.91) for TDF/FTC and 1.29 (1.02, 1.58) for ABC/3TC, the RRs of ICU admission were 0.28 (0.11, 0.90) for TDF/FTC and 1.39 (0.70, 2.80) for ABC/3TC, and the RRs of death were 0.37 (0.23, 1.90) for TDF/FTC and 2.02 (0.88-6.12) for ABC/3TC. The corresponding RRs of hospitalization for TDF/FTC were 0.49 (0.24, 0.81) in individuals =50 years and 1.15 (0.59, 1.93) in younger individuals.Discussion: Compared with other antiretrovirals, TDF/FTC lowers COVID-19 severity among HIV-positive individuals with virological control. This protective effect may be restricted to individuals aged 50 years and older. © 2022 Authors. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0269-9370, 1473-5571

AIDS  LIPPINCOTT WILLIAMS & WILKINS

Tipo:
Article
Páginas:
2171-2179
PubMed:
36382436
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,702 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; COVID-19; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; SARS-CoV-2; Tenofovir; abacavir plus lamivudine; anti human immunodeficiency virus agent; corticosteroid; emtricitabine plus tenofovir alafenamide; emtricitabine plus tenofovir disoproxil; immunosuppressive agent; virus RNA; anti human immunodeficiency virus agent; emtricitabine; lamivudine; tenofovir; adult; antiretroviral therapy; Article; asymptomatic coronavirus disease 2019; attributable risk; CD4 lymphocyte count; chronic kidney failure; clinical outcome; cohort analysis; comorbidity; coronavirus disease 2019; corticosteroid therapy; diabetes mellitus; disease severity; female; follow up; groups by age; hospital admission; hospital mortality; hospitalization; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; hypertension; immunosuppressive treatment; injection drug user; intensive car

Compartir